21-羟化酶缺陷所致经典型先天性肾上腺皮质增生症的管理障碍
本文综述了21-羟化酶缺陷所致经典型先天性肾上腺皮质增生症(CAH)患者及其家庭终身管理中面临的结构性、社会文化与个体层面障碍,包括新生儿筛查、综合照护中心和药物可及性有限,以及污名化、歧视、不良就医体验等;资源不足国家的患者障碍更为突出。照护与药物可及性不足会增加危及生命的肾上腺危象及疾病相关共病风险。
要点
- 结构性障碍包括新生儿筛查、综合照护中心和药物可及性有限。
- 社会文化障碍包括污名化、歧视和不良就医体验。
- 综合照护与药物可及性不足增加肾上腺危象及疾病相关共病风险。
核心结论
- 照护与药物可及性不足会增加危及生命的肾上腺危象及疾病相关共病风险。
- 资源不足国家的个体所面临的障碍往往进一步放大。
研究设计与样本
- 本文为综述,考察CAH患者及其家庭终身管理中所面临的结构性、社会文化与个体障碍。
主要发现
- 结构性障碍包括获得适当新生儿筛查、综合照护中心和药物的机会有限。
- 社会与文化障碍可能包括污名化、歧视和不良就医经历。
- 个体与家庭层面,综合照护可能受受教育程度、经济状况、医疗保险覆盖、地理位置和缺乏社会支持影响。
- 这些障碍对生活在资源不足国家的个体往往进一步放大。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a rare genetic condition that requires lifelong management from birth. Individuals with CAH and their families often face structural barriers to obtaining comprehensive care and treatment, including limited access to appropriate newborn screening, comprehensive care centers, and medications. Social and cultural barriers to care may include stigmatization, discrimination, and adverse medical experiences. At the individual and family level, comprehensive care may be affected by education, finances, health-care coverage, geographic location, and lack of social supports. These barriers are often further magnified for individuals living in underresourced countries. Inadequate access to comprehensive care and medications increases the risk of life-threatening adrenal crisis and disease-related comorbidities. This review article examines the current structural, sociocultural, and individual barriers that individuals with CAH and their families may face when managing their condition throughout their lifetime.
引用
- Eitel KB, Fechner PY. Barriers to the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2025. PMID: 39836619. doi:10.1210/clinem/dgae710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。